New considerations on the management of osteoporosis in Central and Eastern Europe (CEE): Summary of the "3rd Summit on Osteoporosis-CEE", November 2009, Budapest, Hungary

Archives of Osteoporosis

Volumn 6, Issue 1-2, 2011, Pages 1-12

  Lakatos, Péter ^a   Balogh, Ádám ^b   Czerwinski, Edward ^c   Dimai, Hans P ^d   Hans, Didier ^e   Holzer, Gerold ^f   Lorenc, Roman S ^g   Palicka, Vladimir ^h   Obermayer Pietsch, Barbara ^d   Stepan, Jan ^h   Takács, István ^a   Resch, Heinrich ^f  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b UNIVERSITY OF DEBRECEN   (Hungary)

^c JAGIELLONIAN UNIVERSITY   (Poland)

^d MEDICAL UNIVERSITY OF GRAZ   (Austria)

^e LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^f MEDICAL UNIVERSITY OF VIENNA   (Austria)

^g Child Health Institute   (Poland)

^h CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Bone turnover markers; Central and Eastern Europe; Diagnosis and therapy of osteoporosis; FRAX ; Quantitative ultrasound; Secondary osteoporosis

Indexed keywords

BONE TURNOVER; CLINICAL ASSESSMENT TOOL; CLINICAL PRACTICE; CONFERENCE PAPER; CONSENSUS; COST EFFECTIVENESS ANALYSIS; ECHOGRAPHY; ECONOMIC ASPECT; FRACTURE RISK ASSESSMENT TOOL; HUMAN; HUMAN GENETICS; OSTEOLYSIS; OSTEOPOROSIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; RISK FACTOR; SECONDARY OSTEOPOROSIS;

ALGORITHMS; BIOLOGICAL MARKERS; EUROPE, EASTERN; HUMANS; OSTEOPOROSIS; PATIENT COMPLIANCE; RISK ASSESSMENT;

EID: 84856115461     PISSN: 18623522     EISSN: 18623514     Source Type: Journal    
DOI: 10.1007/s11657-010-0048-2     Document Type: Conference Paper

References (39)

1. O'Neil TW, Felsenberg D, Varlow J, Cooper C, Kanis JA, Silman AJ (1996) The prevalence of vertebral deformity in European men and women: the European Vertebral Osteoporosis Study. J Bone Miner Res 11:1010-1018 (Pubitemid 26200053)
2. Strom O, Borgstrom F, Zethraeus N, Johnell O, Lidgren L, Ponzer S, Svensson O, Abdon P, Ornstein E, Ceder L, Thorngren KG, Sernbo I, Jonsson B (2008) Long-term cost and effect on quality of life of osteoporosis-related fractures in Sweden. Acta Orthop 79:269-280 (Pubitemid 351878360)
3. Kanis JA, Johnell O, Oden A, Borgstrom F, Zethraeus N, De Laet C, Jonsson B (2004) The risk and burden of vertebral fractures in Sweden. Osteoporos Int 15:20-26 (Pubitemid 38252435)
4. Lorenc RS, Resch H (2009) Management of osteoporosis in Central and Eastern Europe (CEE): conclusions of the "2nd Summit on Osteoporosis-CEE", 21-22 November 2008, Warsaw, Poland. Arch Osteoporos 4:1-8
5. Franek E, Karczmarewicz E, Misiorowski Wet al (2009) Treatment benefits evaluation in osteoporosis-position of the Summit International Conference on Osteoporosis-Central Eastern Europe held 21-22 November 2008, Warsaw, Poland. Bone 44:S374-S375
6. Marshall D, Johnell O, Wedel H (1996) Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 312:1254-1259 (Pubitemid 26147662)
7. ® algorithm. Curr Osteoporos Rep 7:77-83
8. ® in osteoporosis. Osteoporos Int 21((Suppl 2)):S407-S413
9. ® and nomogram by Nguyen et al.-conformity betweenmethods and their clinical utility. Bone 46:1661-1667
10. Tałałaj M (2009) Bone fracture risk at secondary osteoporoses. Third Central European Congress on Osteoporosis and Osteoarthritis, Krakow, Poland. Abstract L33
11. Lindsay R, Silverman SL, Cooper C, Hanley DA, Barton I, Broy SB, Licata A, Benhamou L, Geusens P, Flowers K, Stracke H, Seeman E (2001) Risk of new vertebral fracture in the year following a fracture. JAMA 285:320-323 (Pubitemid 32095035)
12. Genant HK, Delmas PD, Chen P, Jiang Y, Eriksen EF, Dalsky GP, Marcus R, San Martin J (2007) Severity of vertebral fracture reflects deterioration of bone microarchitecture. Osteoporos Int 18:69-76 (Pubitemid 44885497)
13. Chen P, Krege JH, Adachi JD, Prior JC, Tenenhouse A, Brown JP, Papadimitropoulos E, Kreiger N, Olszynski WP, Josse RG, Goltzman D (2009) Vertebral fracture status and the World Health Organization risk factors for predicting osteoporotic fracture risk. J Bone Miner Res 24:495-502
14. Bone Health and Osteoporosis: a report of the surgeon general 2004. U.S. Department of Health and Human Services, Public Health Service, Office of the Surgeon General, Rockville, MD, US; http:// www.surgeongeneral.gov/library/ bonehealth/Executive-Summary. html#Chapter8AssessingtheRiskofBoneDiseaseandFracture, accessed 2 July 2010
15. Kanis JA, Johnell O, Oden A, Johansson H, De Laet C, Eisman JA, Fujiwara S, Kroger H, McCloskey EV, Mellstrom D, Melton LJ, Pols H, Reeve J, Silman A, Tenenhouse A (2005) Smoking and fracture risk: a meta-analysis. Osteoporos Int 16:155-162 (Pubitemid 40193202)
16. van Staa TP, Leufkens HG, Cooper C (1991) The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 13:777-787
17. Meenan RF, Kazis LE, Anthony JM, Wallin BA (1991) The clinical and health status of patients with recent-onset rheumatoid arthritis. Arthritis Rheum 34:761-765
18. Kanis JA, Burlet N, Cooper C, Delmas PD, ReginsterJ-Y BF, Rizzoli R (2008) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 19:399-428
19. Greenspan SL, Resnick NM, Parker RA (2005) Early changes in biochemical markers of bone turnover are associated with longterm changes in bone mineral density in elderly women on alendronate, hormone replacement therapy, or combination therapy: a three-year, double-blind, placebo-controlled, randomized clinical trial. J Clin Endocrinol Metab 90:2762-2767 (Pubitemid 40686321)
20. Chen P, Satterwhite JH, Licata AA, Lewiecki EM, Sipos AA, Misurski DM, Wagman RB (2005) Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. J Bone Miner Res 20:962-970 (Pubitemid 40712820)
21. Stepan JJ, Zikán V (2003) Calcitonin load test to assess the efficacy of salmon calcitonin. Clin Chim Acta 336:49-55 (Pubitemid 37324753)
22. Holzer G, Noske H, Lang T, Holzer L, Willinger U (2005) Soluble cathepsin K: a novel marker for the prediction of nontraumatic fractures? J Lab Clin Med 146:13-17 (Pubitemid 40982014)
23. Palomba S, Orio F Jr, Russo T, Falbo A, Tolino A, Manguso F, Nunziata V, Mastrantonio P, Lombardi G, Zullo F (2005) BsmI vitamin D receptor genotypes influence the efficacy of antiresorptive treatments in postmenopausal osteoporotic women. A 1-year multicenter, randomized and controlled trial. Osteoporos Int 16:943-952 (Pubitemid 41127104)
24. Hellman J, Käkönen SM, Matikainen MT, Karp M, Lövgren T, Väänänen HK, Pettersson K (1996) Epitope mapping of nine monoclonal antibodies against osteocalcin: combinations into two-site assays affect both assay specificity and sample stability. J Bone Miner Res 11:1165-1175 (Pubitemid 26321367)
25. Seibel MJ, Lang M, Geilenkeuser WJ (2001) Interlaboratory variation of biochemical markers of bone turnover. Clin Chem 47:1443-1450 (Pubitemid 32678824)
26. Faulkner KG, von Stetten E, Miller P (1999) Discordance in patient classification using T-scores. J Clin Densitom 2:343-350
27. Kanis JA, Adams J, Borgström F, Cooper C, Jönsson B, Preedy D, Selby P, Compston J (2008) The cost-effectiveness of alendronate in the management of osteoporosis. Bone 42:4-15
28. Kanis J (2009) International Osteoporosis Foundation, 8th European Union osteoporosis consultation panel meeting, Brussels, Belgium. http://www. iofbonehealth.org/download/osteofound/filemanager/policy-advocacy/ EU-consultation-panel-meetings/8th-EU-consultationpanel-meeting071009.pdf, accessed 2 July 2010
29. Report of the International Osteoporosis Foundation 2008: osteoporosis in the European Union in 2008: 10 years of progress and ongoing challenges. http://www.sante.public.lu/publications/ maladies-traitements/osteoporose/ osteoporosis-eu-2008/osteoporosiseu- 2008.pdf, accessed 2 July 2010
30. Cramer JA, Amonkar MM, Hebborn A, Altman R (2005) Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 21:1453-1460 (Pubitemid 41368578)
31. Seeman E, Compston J, Adachi J, Brandi ML, Cooper C, Dawson-Hughes B, Jönsson B, Pols H, Cramer JA (2007) Noncompliance: the Achilles' heel of anti-fracture efficacy. Osteoporos Int 18:711-719 (Pubitemid 46684777)
32. Huybrechts KF, Ishak KJ, Caro JJ (2006) Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone 38:922-928 (Pubitemid 44498580)
33. Ström O, Borgström F, Kanis JA, Jönsson B (2009) Incorporating adherence into health economic modelling of osteoporosis. Osteoporos Int 20:23-34
34. Canalis E, Giustina A, Bilezikian JP (2007) Mechanisms of anabolic therapies for osteoporosis. N Engl J Med 357:905-916
35. Rivadeneira F, Styrkársdottir U, Estrada K et al (2009) Twenty bone-mineral-density loci identified by large-scale meta-analysis of genome-wide association studies. Nat Genet 41:1199-1206
36. Little RD, Carulli JP, Del Mastro RG et al (2002) A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am J Hum Genet 70:11-19 (Pubitemid 34031693)
37. GongY, Slee RB, Fukai Net al (2001) LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 107:513-523 (Pubitemid 33152786)
38. Levasseur R, Lacombe D, de Vernejoul MC (2005) LRP5 mutations in osteoporosis-pseudoglioma syndrome and highbone- mass disorders. Joint Bone Spine 72:207-214 (Pubitemid 40591760)
39. van Meurs JB, Trikalinos TA, Ralston SH et al (2008) Large-scale analysis of association between LRP5 and LRP6 variants and osteoporosis. JAMA 299:1277-1290 (Pubitemid 351439074)